3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
7
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Multiple Myeloma
3
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Erdheim-Chester Disease
2
Xanthogranuloma, Juvenile
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Pancreatic Adenocarcinoma
1
Neoplasms, Unknown Primary
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoproliferative Disorders
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Laryngeal Neoplasms
1
Inflammatory Breast Neoplasms
1
Histiocytosis, Sinus
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Histiocytic Disorders, Malignant
1
Interventions
pembrolizumab
2
atezolizumab
2
Paclitaxel
2
Carboplatin
2
veliparib
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
entrectinib
1
cobimetinib
1
alectinib
1
Whole Genome Sequencing
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Taxes
1
Surveys and Questionnaires
1
Specimen Handling
1
Sequence Analysis, RNA
1
Radiosurgery
1
Magnetic Resonance Spectroscopy
1
HhAntag691
1
Genetic Testing
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Erlotinib Hydrochloride
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
cobimetinib
×
1 year
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts